Amgen (AMGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Amgen (AMGN) reported $9.18 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 9.4%. EPS of $6.02 for the same period compares to $4.97 a year ago.The reported revenue represents a surprise of +3.52% over the Zacks Consensus Estimate of $8.87 billion. With the consensus EPS estimate being $5.26, the EPS surprise was +14.45%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Amgen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Product Sales- Neulasta- ROW: $19 million versus the seven-analyst average estimate of $23.31 million. The reported number represents a year-over-year change of -36.7%.Product Sales- Neulasta- U.S.: $63 million compared to the $70.64 million average estimate based on seven analysts. The reported number represents a change of -16% year over year.Product Sales- Otezla- ROW: $106 million compared to the $112.78 million average estimate based on six analysts. The reported number represents a change of -5.4% year over year.Product Sales- Nplate- U.S.: $228 million versus the six-analyst average estimate of $227.77 million. The reported number represents a year-over-year change of +6.5%.Revenue- Product sales: $8.77 billion versus $8.5 billion estimated by 10 analysts on average. Compared to the year-ago quarter, this number represents a +9.1% change.Product Sales- Neulasta- Total: $82 million versus $94.77 million estimated by 10 analysts on average. Compared to the year-ago quarter, this number represents a -21.9% change.Revenue- Other revenues: $408 million versus the 10-analyst average estimate of $345.97 million. The reported number represents a year-over-year change of +17.6%.Product Sales- Vectibix- Total: $305 million compared to the $277.53 million average estimate based on 10 analysts. The reported number represents a change of +13% year over year.Product Sales- KYPROLIS- Total: $378 million versus the 10-analyst average estimate of $365.78 million. The reported number represents a year-over-year change of +0.3%.Product Sales- BLINCYTO- Total: $384 million versus the 10-analyst average estimate of $385.77 million. The reported number represents a year-over-year change of +45.5%.Product Sales- Enbrel- Total: $604 million versus $804.22 million estimated by 10 analysts on average. Compared to the year-ago quarter, this number represents a -33.6% change.Product Sales- LUMAKRAS/LUMYKRAS- Total: $90 million versus the 10-analyst average estimate of $90.65 million. The reported number represents a year-over-year change of +5.9%.View all Key Company Metrics for Amgen here>>>Shares of Amgen have returned +3.1% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity.Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amgen Inc. (AMGN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks